Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, Stepping Into Diagnostics, Pens Biomarker Collaboration With Mayo Clinic

NEW YORK, Dec. 7 (GenomeWeb News) - Invitrogen and the Mayo Clinic will co-develop diagnostic biomarkers and the technologies to detect them, the two organizations said yesterday.

 

The aim of the collaboration---which marks the first time Invitrogen has stepped directly into the field of diagnostics--is to develop new diagnostic and prognostic tests for cancer and general laboratory medicine.

 

In the deal, Invitrogen will provide research tools, which include human protein microarrays, engineered cell lines, cell-based assays, and cloning and expression technologies. The Mayo Clinic will contribute patient samples and expertise in diagnostic assays. Invitrogen can license technologies resulting from the collaboration either exclusively or non-exclusively, in exchange for funding several biomarker research programs at Mayo.


"Our objective with this agreement is to generate new enabling technologies for doctors, patients and the larger health-care community," Invitrogen CEO Greg Lucier said in a statement.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.